Indikation | Kurzbezeichnung | EudraCT-Nr. | Phase | Titel |
---|---|---|---|---|
NHL agg | GCT3013-05 | 2020-003016-27 | III | Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma. |
NHL agg | PTLD Register | n/a | n/a | Nichtinterventionelle, prospektive Registerstudie zur Behandlungspraxis der PTLD in der klinischen Routine |
NHL agg. | CHART Review | Register | ||
NHL agg. | ImbruVeR CHOP | 2015-003429-32 | Ibrutinib, Bortezomib s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2 | |
NHL agg. | GCT2013-01 | 2017-001748-36 | I - II | A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma |
NHL agg. | Daly2, M-2020-371 | 2020-003908-14 | II | A pivotal Phase II randomised, multi-centre, open-label study to exalsate the effieacy and safety of MB-CÄRTZ{)19.1 compared ta standard af care therapy in participants ltrith relapsed/refractory: diffuse large B-cell lymphorna (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation |
NHL agg. | MB-CART2019.1, M-2018-331 | 2018-001253-27 | I - II | A Phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or refractory CD20 and CD19 positive B-NHL |
NHL agg. | DSHNHL 2015-1 , NIVEAU | 2016-002272-27 | n/a | Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease |
NHL agg. | Optimate | 2018-002115-96 | III | OptiMATe - Optimizing MATRix as remission induction for PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial“ |
CLL | CLL 17 | 2019-003854-99 | III | A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL) |
CLL | CLL Frail | II | A PROSPECTIVE, MULTICENTRE PHASE-II TRIAL OF ACALABRUTINIB IN VERY OLD (>80Y) OR FRAIL PATIENTS WITH CLL |
|
CLL | CLL Register | n/a | n/a | Registry of the German CLL Study Group: Long term follow-up of patients with CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL and Richter´s transformation |
CLL | CLL RT1 | 2018-002492-17 | II | A Prospective, Open-Label, Multicentre Phase-II-Trial To Evaluate The Efficacy And Safety Of Zanubrutinib (BGB-3111), A BTK Inhibitor, Plus Teslelizumab (BGB-A317), A PD-1 Inhibitor, For Treatment Of Patients With Richter Transformation (CLL-RT1-Trial Of The GCLLSG) |
MZoL | OLYMP-1 | 2017-003149-56 | II | Phase II, single arm, multicentric, open label, non-randomized: Obinutuzumab in marginal zone lymphoma |
MZoL | Marginalzonenlymphom-Register | n/a | n/a | Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen |
NHL ind. | Alternative C | 2018-004038-13 | II | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free. Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden |
AML | IDH2-Post Allo | n/a | n/a | Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation |
ALL | GMALL 08/2013 | 2013-003466-13 | IV | Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie |
ALL | ALL-Register | n/a | n/a | GMALL ALL-Register |
MPN | IMG-7289-CTP-201 | 2019-003659-13 | II | A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia |
MPN | IMG-7289-CTP-202 | 2021-002452-37 | II | A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study |
PNH | PNH-Register | n/a | n/a | M07-001, 914007 Register für paroxysmale nächtliche Hämoglobinurie (PNH) |
PNH | CLNP023X2201 | 2017-000888-33 | II | An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis |
PNH | BP39144 | 2016-002128-10 | I/II | An adaptive phase I/II study to assess safety, efficacy, phamacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) |
PNH | BO42162 Commodore 2 naive | 2019-004931-21 | III | A phase 3, randomized, open label, active controlles, multicenter study, evaluating the efficacy and safety of Crovalimab versus Eculizumab in Adult and andolescent patients with paroxismal nocturnal Hemoglobinuria not previously treated with complement inhibitors. |
PNH | APL2-307 | 2019-001106-23 | III | An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). |
PNH | BO42161 Commodore 1 switch | 2019-004931-21 | III | A Phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in adult and adolescent patients with PNH currently treated with complement inhibitors |
PNH | CLNP023C12302 | 2019-004665-40 | III | A randomized, multicenter, active-comparator controlled, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatment with an intravenous anti-C5 antibody |
PNH | CLNP023C12301 | 2020-003172-41 | III | A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naive to complement inhibitor therapy |
PNH | RavuReWo | n/a | III | Analysis/Outcomes of Patients who switched from being under eculizumab to ravulizumab treatment in a real-world setting – according to the label but not included in Phase 3 studies RavuReWo |
Anämie | MOM-M281-006 | 2019-000720-17 | II - III | Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study with a Long-term Open-label Extension |
Anämie | EMAA 9345 | 2014-000174-19 | II - III | Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A. Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade ®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A |
Anämie | C-935788-058 (Extension) | 2019-001882-34 | III | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
CAD | PDY16370 BIVV020 | 2019-001844-22 | 1b | A multicenter, Phase 1b, open label, nonrandomized, single dose study evaluating the safety, tolerability and activity of BIVV020 in adults with cold agglutinin disease |
CAD | ACT16832 | 2020‐003880‐24 | 1b - II | A multicenter, open-label, Phase 1b/2 study to evaluate the safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in patients with primary warm autoimmune hemolytic anemia |
CAD | LTS16637 | 2019-004423-21 | 1b | An open label, long term, safety and tolerability study of patients with cold agglutinin disease previously treated with BIVV020 |
ITP | ARGX-113-1803 | 2019-002100-41 | III | A Long-Term, Single-Arm, Open-Label, Multicenter, Phase III Follow-On Trial to Evaluate Safety and Efficacy of Intravenous Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia |
ITP | ARGX-113-1801 | 2019-002100-41 | III | A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia |
ITP | PDY16894 | 2020-00416-18 | Iia | A multicenter, phase 2a, open label, nonrandomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic immune thrombocytopenia (ITP)” |
ITP / CAD | CLNP023L12201 | 2021-002039-40 | II | An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan(LNP023) in participants with autoimmune benignhematological disorders |
Waiha | ANX-wAIHA-01 | n/a | n/a | “A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia “ |
MM | Regeneron 5458-ONC-1826 | n/a | I - II | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
MM | GMMG-CONCEPT | 2016-000432-17 | II | Eine klinische Phase II Studie zur Induktions-, Konsolidierungs- und Erhaltungstherapie mit Isatuximab, Carfilzomib, Lenalidomid und Dexamethason (I-KRd) in der Primärtherapie des Hochrisikomyeloms |
AL-Amyloidose | CAEL301-301 | 2019‐004254‐28 | III | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis |
AL-Amyloidose | CAEL301-302 | 2020-000713-32 | III | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis |
AL-Amyloidose | Amyloidose Register | n/a | n/a | Nationales klinisches Amyloidose-Register |